Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said.
The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information submitted by manufacturers.
Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s.
• Subscribe to ITV News on YouTube: http://bit.ly/2lOHmNj
• Get breaking news and more stories at http://www.itv.com/news
Follow ITV News on TikTok https://www.tiktok.com/@itvnews?lang=en
Follow ITV News on Instagram: https://www.instagram.com/itvnews/
Follow ITV News on Facebook: https://www.facebook.com/itvnews/
Follow ITV News on X: https://twitter.com/itvnews
